Skip to main content
. 2017 Sep 19;108(11):2265–2272. doi: 10.1111/cas.13386

Figure 3.

Figure 3

Combinational treatment with sorafenib (SOR) and betulinic acid (BA) significantly reduces the colony‐forming ability of A549, H358 and A427 cells as compared to either compound alone. Long‐term colony formation assay. On the left: representative images of colonies formed by A549, H358 and A427 cells after treatment with 1.3 μg/mL sorafenib and 3 μg/mL betulinic acid alone and in combination. On the right: the surviving fraction (SF) of A549, H358 and A427 cells after treatment with 1.3 μg/mL sorafenib and 3 μg/mL betulinic acid alone and in combination (n = 3). *P < 0.05, **P < 0.01 compared with sorafenib treatment group and betulinic acid treatment group.